[Comment] End of transplantation's reign in mantle cell lymphoma

Autologous stem-cell transplantation (ASCT) has remained central to the care of younger patients with mantle cell lymphoma since the publication of the first European Mantle Cell Lymphoma Network trial in 2005.1 Its role is now firmly challenged in The Lancet by results of the TRIANGLE study from Martin Dreyling and colleagues.2